TransMedics Group, Inc. Financials

Market Capitalization $2.10 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	67.26
Forward PE	37.91
Price to Sales TTM	$5.23
Price to Book MRQ	$10.00
Enterprise to Revenue	5.70
Enterprise to EBITDA	44.73

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	8.14%
Operating Margin	3.61%
Return on Assets TTM	2.84%
Return on Equity TTM	19.41%

Income Statement

Revenue TTM	$401,089,984
Revenue per Share TTM	$12.16
Quarterly Revenue Growth	63.70%
Gross Profit TTM	$237,992,000
EBITDA	$64,280,000
Net Income to Common TTM	$32,638,000
Diluted EPS TTM	$0.93
Quarterly Earnings Growth YoY	63.72%

Balance Sheet

Total Cash MRQ	$330,094,016
Total Cash per Share MRQ	$9.84
Total Debt MRQ	$
Total Debt to Equity MRQ	246.83
Current Ratio MRQ	8.20
Book Value per Share MRQ	$6.26

Cash Flow

Operating Cash Flow TTM	$37,444,000
Levered Free Cash Flow TTM	$-142,587,504

TMDX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	33,561,500
Float Shares	32,545,274
Avg 10 Volume	3,463,910
Avg 30 Volume	None
Shares Short	9,153,451
Short Ratio	5.42
Short % of Shares	33.17%
% Held by Insiders	3.21%
% Held by Institutions	113.30%

Stock Price Summary

Beta	2.07
Fifty Two Week Low	$55.00
Fifty Two Week High	$177.37
Fifty Two Week Change	-45.81%
Day 50 MA	$71.13
Day 200 MA	$119.53

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date